Your browser is no longer supported. Please, upgrade your browser.
IRWD Ironwood Pharmaceuticals, Inc. monthly Stock Chart
IRWD [NASD]
Ironwood Pharmaceuticals, Inc.
Index- P/E18.99 EPS (ttm)0.54 Insider Own2.00% Shs Outstand158.37M Perf Week11.23%
Market Cap1.61B Forward P/E17.68 EPS next Y0.58 Insider Trans-2.55% Shs Float154.70M Perf Month3.45%
Income84.10M PEG- EPS next Q0.14 Inst Own- Short Float16.06% Perf Quarter0.10%
Sales439.60M P/S3.66 EPS this Y129.70% Inst Trans1.10% Short Ratio11.11 Perf Half Y-16.50%
Book/sh-0.45 P/B- EPS next Y28.79% ROA5.90% Target Price12.20 Perf Year6.47%
Cash/sh- P/C- EPS next 5Y- ROE-16.00% 52W Range7.91 - 14.10 Perf YTD-23.37%
Dividend- P/FCF459.47 EPS past 5Y17.80% ROI28.30% 52W High-27.66% Beta1.47
Dividend %- Quick Ratio12.10 Sales past 5Y41.20% Gross Margin94.30% 52W Low28.95% ATR0.45
Employees317 Current Ratio12.10 Sales Q/Q16.30% Oper. Margin20.30% RSI (14)56.01 Volatility5.43% 4.66%
OptionableYes Debt/Eq- EPS Q/Q114.80% Profit Margin4.90% Rel Volume0.95 Prev Close10.09
ShortableYes LT Debt/Eq- EarningsAug 06 BMO Payout0.00% Avg Volume2.24M Price10.20
Recom2.70 SMA203.67% SMA503.03% SMA200-7.56% Volume2,131,206 Change1.09%
Jun-17-20Initiated Northland Capital Outperform $14
Jul-10-19Resumed Credit Suisse Neutral
Mar-27-19Upgrade Morgan Stanley Underweight → Equal-Weight
Feb-25-19Upgrade H.C. Wainwright Sell → Neutral $14
Jan-24-19Upgrade JP Morgan Underweight → Neutral
Nov-07-18Downgrade JP Morgan Neutral → Underweight
Nov-07-18Downgrade Credit Suisse Outperform → Neutral
Jul-23-18Initiated H.C. Wainwright Sell $12.50
May-09-18Downgrade Morgan Stanley Equal-Weight → Underweight
Jan-05-18Downgrade BofA/Merrill Buy → Underperform
Dec-06-17Downgrade Mizuho Buy → Neutral $16
Jul-21-17Downgrade JP Morgan Overweight → Neutral
May-03-17Initiated Wells Fargo Outperform
Apr-07-17Reiterated Mizuho Buy $21 → $22
Feb-22-17Reiterated Barclays Equal Weight $13 → $16
Nov-04-16Reiterated Mizuho Buy $19 → $20
Oct-24-16Reiterated Wedbush Neutral $10 → $13
Oct-10-16Reiterated Mizuho Buy $24 → $19
Sep-27-16Reiterated WallachBeth Hold $15 → $17
Jul-15-16Reiterated Mizuho Buy $16 → $24
Aug-07-20 02:52PM  
11:18AM  
Aug-06-20 10:45AM  
07:00AM  
Jul-30-20 12:33PM  
Jul-23-20 04:05PM  
12:17PM  
Jul-21-20 07:00AM  
Jul-12-20 07:40PM  
Jun-08-20 02:51AM  
Jun-05-20 11:31AM  
Jun-03-20 09:56AM  
09:04AM  
08:32AM  
May-28-20 09:10AM  
May-27-20 08:51AM  
08:00AM  
May-11-20 06:53AM  
May-07-20 10:00PM  
10:56AM  
May-06-20 07:15PM  
04:05PM  
Apr-29-20 12:34PM  
Apr-28-20 04:05PM  
Apr-16-20 04:05PM  
12:10PM  
Apr-10-20 08:49AM  
Apr-07-20 03:32PM  
Mar-26-20 09:00AM  
Mar-14-20 11:30AM  
Feb-26-20 04:05PM  
Feb-25-20 04:05PM  
Feb-20-20 11:13AM  
Feb-14-20 09:50AM  
Feb-13-20 09:45AM  
08:48AM  
07:00AM  
Feb-10-20 12:38PM  
10:13AM  
Feb-06-20 12:31PM  
Jan-30-20 04:05PM  
Jan-22-20 09:20AM  
Jan-06-20 08:00AM  
Jan-02-20 04:01PM  
09:35AM  
Dec-31-19 08:58AM  
Dec-27-19 12:00PM  
Dec-26-19 09:00AM  
Dec-25-19 11:30AM  
Dec-23-19 08:33AM  
Dec-19-19 07:34PM  
Dec-18-19 09:23AM  
Dec-13-19 08:39AM  
Dec-10-19 09:15AM  
08:33AM  
Dec-09-19 10:20AM  
Dec-03-19 08:51AM  
Nov-29-19 09:39AM  
Nov-27-19 08:21AM  
Nov-26-19 09:36AM  
Nov-22-19 09:48AM  
Nov-21-19 12:15PM  
Nov-19-19 09:13AM  
Nov-11-19 09:21AM  
Nov-08-19 09:24AM  
08:00AM  
Nov-06-19 02:23PM  
10:36AM  
10:20AM  
Nov-05-19 04:05PM  
Nov-01-19 10:52AM  
Oct-31-19 09:05AM  
07:00AM  
Oct-30-19 08:17AM  
Oct-28-19 10:23AM  
08:00AM  
Oct-24-19 10:32AM  
Oct-17-19 04:05PM  
Oct-11-19 08:14AM  
Sep-19-19 02:31PM  
Sep-18-19 07:39AM  
02:00AM  
Sep-13-19 11:08AM  
Sep-10-19 03:18PM  
Sep-04-19 10:31AM  
Aug-30-19 06:14PM  
Aug-28-19 04:05PM  
Aug-27-19 08:05AM  
Aug-13-19 04:50PM  
07:30AM  
07:30AM  
Aug-08-19 07:30AM  
Aug-06-19 04:05PM  
Aug-03-19 04:45AM  
Jul-31-19 10:58AM  
06:00AM  
04:24AM  
Jul-30-19 08:45PM  
04:01PM  
Jul-23-19 10:32AM  
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the Canada and European Union; MD-7246, an oral, intestinal, non-opioid, pain-relieving agent for patients suffering from abdominal pain associated with GI diseases; and IW 3718, a gastric retentive formulation of a bile acid sequestrant, which is in Phase III clinical trials for the treatment of GERD. Ironwood Pharmaceuticals, Inc. has collaboration agreements with Allergan plc and AstraZeneca AB to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other gastrointestinal (GI) conditions in North America, China, Hong Kong, Macau, and Japan, as well as a license agreement with Astellas Pharma Inc. to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other GI conditions in Japan. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was founded in 1998 and is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
OLANOFF LAWRENCE SDirectorJun 10Sale10.0611,350114,18168,629Jun 12 04:32 PM
Rickard JasonSVP, Chief Operating OfficerMay 11Sale10.355105,279234,580May 13 05:23 PM
MCCOURT Thomas APresidentMay 11Sale10.351,69717,564319,847May 13 05:22 PM
MacDonald KellyChief Accounting OfficerMay 11Sale10.351,15311,934118,147May 13 05:20 PM
Mallon MarkChief Executive OfficerMay 11Sale10.3523,206240,182501,280May 13 05:21 PM
Kilroy ConorSVP, GC & SecretaryMay 11Sale10.357167,411128,921May 13 05:19 PM
Mallon MarkChief Executive OfficerFeb 24Sale11.25111303,425Feb 25 04:45 PM
Mallon MarkChief Executive OfficerFeb 21Sale11.637,98392,842303,426Feb 25 04:45 PM
MCCOURT Thomas APresidentFeb 21Sale11.634,17748,579221,062Feb 25 04:37 PM
MacDonald KellyChief Accounting OfficerFeb 21Sale11.633,90045,35783,127Feb 25 04:36 PM
Gilbert Halley EChief Admin Officer & SVPFeb 21Sale11.6315,328178,265265,991Feb 25 04:33 PM
Consylman GinaSVP, CFO & TreasurerFeb 21Sale11.6312,501145,387202,787Feb 25 04:31 PM
Gilbert Halley EChief Admin Officer & SVPJan 31Option Exercise10.0260,000601,200341,319Feb 04 04:02 PM
Gilbert Halley EChief Admin Officer & SVPJan 31Sale12.0560,000723,000281,319Feb 04 04:02 PM
MCCOURT Thomas APresidentJan 24Option Exercise10.0220,000200,400245,239Jan 28 04:02 PM
MCCOURT Thomas APresidentJan 24Sale12.7120,000254,200225,239Jan 28 04:02 PM
Currie Mark GDirectorJan 23Option Exercise9.1260,000547,200609,272Jan 24 04:43 PM
Currie Mark GDirectorJan 23Sale12.5960,000755,400549,272Jan 24 04:43 PM
Currie Mark GDirectorJan 16Option Exercise10.028,88889,058558,160Jan 21 05:23 PM
Currie Mark GDirectorJan 16Sale12.808,888113,766549,272Jan 21 05:23 PM
MacDonald KellyChief Accounting OfficerNov 08Sale11.0098710,85778,337Nov 12 06:26 PM
Consylman GinaSVP, CFO & TreasurerNov 08Sale11.001,51016,610174,138Nov 12 06:23 PM
MCCOURT Thomas APresidentAug 30Option Exercise4.88220,0001,073,600329,739Sep 04 04:42 PM
MCCOURT Thomas APresidentAug 30Sale9.24220,0002,032,800109,739Sep 04 04:42 PM
Consylman GinaSVP, CFO & TreasurerAug 16Sale9.042121,916175,648Aug 20 05:37 PM